Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ACRO BIOMEDICAL CO., LTD. (ACBM)
|
Add to portfolio |
|
|
|
| Price: |
$4.77
| | Metrics |
| OS: |
60.0
|
M
| |
|
|
| Market cap: |
$286
|
M
| |
|
|
|
Net cash:
|
|
| |
|
|
|
EV:
|
$286
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($8.0)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
| Date Filed | Type | Description |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/02/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 07/21/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 04/03/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 11/21/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/14/2022 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 08/12/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Sep-30-19 | Sep-30-18 | Sep-30-17 | Sep-30-16 | Sep-30-15 |
| Revenues | 1.2 | 0.7 | 0.2 | 1.4 | 8.0 | 0.5 | 0.0 | 0.0 |
| Revenue growth | 74.1% | 255.5% | | -83.1% | 1471.5% | | | |
| Cost of goods sold | 0.9 | 0.5 | 0.2 | 1.2 | 7.2 | 0.5 | 0.0 | 0.0 |
| Gross profit | 0.3 | 0.2 | 0.0 | 0.1 | 0.8 | 0.1 | 0.0 | 0.0 |
| Gross margin | 21.7% | 23.2% | 6.3% | 10.0% | 10.4% | 10.0% | | |
| Selling, general and administrative | 2.7 | 0.3 | 0.4 | 0.6 | 0.3 | 0.1 | 0.0 | 0.0 |
| General and administrative | | | | | | | 0.0 | |
| EBIT | -2.4 | -0.1 | -0.4 | -0.4 | 0.5 | 0.0 | 0.0 | 0.0 |
| EBIT margin | -201.1% | -19.0% | -218.4% | -32.6% | 6.4% | -0.4% | | |
| Pre-tax income | -7.7 | -0.1 | -0.4 | -0.4 | 0.5 | 0.0 | 0.0 | 0.0 |
| Income taxes | 0.0 | 0.0 | -0.1 | -0.1 | 0.1 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 13.3% | 12.5% | 16.5% | 18.0% | 0.0% | 0.0% | 0.0% |
| Net income | -7.7 | -0.1 | -0.4 | -0.4 | 0.4 | 0.0 | 0.0 | 0.0 |
| Net margin | -642.8% | -17.1% | -192.0% | -27.4% | 5.2% | -0.4% | | |
| |
| Diluted EPS | ($0.14) | $0.00 | ($0.01) | ($0.01) | $0.01 | $0.00 | $0.00 | $0.00 |
| Shares outstanding (diluted) | 53.8 | 47.8 | 47.8 | 47.8 | 47.7 | 47.2 | 47.2 | 14.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|